Nxera pharma's partner neurocrine biosciences initiates phase 1 clinical study evaluating effects of nbi-1117567 in healthy adults

Tokyo, japan and cambridge, uk, 9 may 2024 – nxera pharma (“the company” or “nxera”; tse: 4565) notes that its partner neurocrine biosciences inc. (“neurocrine”; nasdaq: nbix), a leading neuroscience-focused biopharmaceutical company, announced that it has initiated its phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound nbi-1117567 in healthy adult participants – see neurocrine press announcement here .
NBIX Ratings Summary
NBIX Quant Ranking